Vicore Pharma Holding AB
Vicore Pharma is an innovative clinical-stage biopharmaceutical company dedicated to creating life-changing treatments in diseases where the AT2 receptor has a central role.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Vicore Pharma is an innovative clinical-stage biopharmaceutical company dedicated to creating life-changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology. The company was founded in the early 2000s based on the design and synthesis of buloxibutid by Professor Anders Hallberg’s group at Uppsala University. Vicore Pharma is unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's headquarter is situated in Stockholm, Sweden.
History
Vicore Pharma was founded in the early 2000s based on the design and synthesis of buloxibutid by Professor Anders Hallberg’s group at Uppsala University. The company is an innovative clinical-stage biopharmaceutical company dedicated to creating life-changing treatments in diseases where the AT2 receptor has a central role. It is unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/vicore-pharma-holding-ab · Editorial policy · How profiles are compiled